Page 59 - Read Online

Morgan et al. HOX genes and the tumor microenvironment

104. Traktuev DO, Tsokolaeva ZI, Shevelev AA, Talitskiy KA, Stepanova 9 to fibrin: activation via a plasmin-dependent pathway. Inflammation
VV, Johnstone BH, Rahmat-Zade TM, Kapustin AN, Tkachuk 1998;22:287-305.
VA, March KL, Parfyonova YV. Urokinase gene transfer augments 115. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays
angiogenesis in ischemic skeletal and myocardial muscle. Mol Ther 1992;14:455-63.
2007;15:1939-46. 116. Okumura Y, Sato H, Seiki M, Kido H. Proteolytic activation of the
105. Cubellis MV, Nolli ML, Cassani G, Blasi F. Binding of single-chain precursor of membrane type 1 matrix metalloproteinase by human
prourokinase to the urokinase receptor of human U937 cells. J Biol plasmin. A possible cell surface activator. FEBS Lett 1997;402:181-4.
Chem 1986;261:15819-22. 117. Alexander RA, Prager GW, Mihaly-Bison J, Uhrin P, Sunzenauer S,
106. Kwak SH, Mitra S, Bdeir K, Strassheim D, Park JS, Kim JY, Idell Binder BR, Schutz GJ, Freissmuth M, Breuss JM. VEGF-induced
S, Cines D, Abraham E. The kringle domain of urokinase-type endothelial cell migration requires urokinase receptor (uPAR)-
plasminogen activator potentiates LPS-induced neutrophil activation dependent integrin redistribution. Cardiovasc Res 2012;94:125-35.
through interaction with {alpha}V{beta}3 integrins. J Leukoc Biol 118. Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD.
2005;78:937-45. The receptor for urokinase type plasminogen activator polarizes
107. Mazar AP, Henkin J, Goldfarb RH. The urokinase plasminogen expression of the protease to the leading edge of migrating monocytes
activator system in cancer: implications for tumor angiogenesis and and promotes degradation of enzyme inhibitor complexes. J Cell Biol
metastasis. Angiogenesis 1999;3:15-32. 1990;111:783-92.
108. Nykjaer A, Kjoller L, Cohen RL, Lawrence DA, Garni-Wagner 119. Prager GW, Breuss JM, Steurer S, Olcaydu D, Mihaly J, Brunner
BA, Todd RF, 3rd, van Zonneveld AJ, Gliemann J, Andreasen PA. PM, Stockinger H, Binder BR. Vascular endothelial growth factor
Regions involved in binding of urokinase-type-1 inhibitor complex receptor-2-induced initial endothelial cell migration depends on the
and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/ presence of the urokinase receptor. Circ Res 2004;94:1562-70.
low density lipoprotein receptor-related protein. Evidence that the 120. Ferrara N. Binding to the extracellular matrix and proteolytic
urokinase receptor protects pro-urokinase against binding to the processing: two key mechanisms regulating vascular endothelial
endocytic receptor. J Biol Chem 1994;269:25668-76. growth factor action. Mol Biol Cell 2010;21:687-90.
109. Pluskota E, Soloviev DA, Bdeir K, Cines DB, Plow EF. Integrin 121. Matsuno H, Kozawa O, Yoshimi N, Akamatsu S, Hara A, Mori
alphaMbeta2 orchestrates and accelerates plasminogen activation and H, Okada K, Ueshima S, Matsuo O, Uematsu T. Lack of alpha2-
fibrinolysis by neutrophils. J Biol Chem 2004;279:18063-72. antiplasmin promotes pulmonary heart failure via overrelease of
110. Tarui T, Akakura N, Majumdar M, Andronicos N, Takagi J, Mazar AP, VEGF after acute myocardial infarction. Blood 2002;100:2487-93.
Bdeir K, Kuo A, Yarovoi SV, Cines DB, Takada Y. Direct interaction 122. Park JE, Keller GA, Ferrara N. The vascular endothelial growth
of the kringle domain of urokinase-type plasminogen activator (uPA) factor (VEGF) isoforms: differential deposition into the subepithelial
and integrin alpha v beta 3 induces signal transduction and enhances extracellular matrix and bioactivity of extracellular matrix-bound
plasminogen activation. Thromb Haemost 2006;95:524-34. VEGF. Mol Biol Cell 1993;4:1317-26.
111. Miles LA, Greengard JS, Griffin JH. A comparison of the abilities 123. Koolwijk P, van Erck MG, de Vree WJ, Vermeer MA, Weich HA,
of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to Hanemaaijer R, van Hinsbergh VW. Cooperative effect of TNFalpha,
activate plasminogen. Thromb Res 1983;29:407-17. bFGF, and VEGF on the formation of tubular structures of human
112. Peltz SW, Hardt TA, Mangel WF. Positive regulation of activation microvascular endothelial cells in a fibrin matrix. Role of urokinase
of plasminogen by urokinase: differences in Km for (glutamic acid)- activity. J Cell Biol 1996;132:1177-88.
plasminogen and lysine-plasminogen and effect of certain alpha, 124. Saksela O, Rifkin DB. Release of basic fibroblast growth factor-
omega-amino acids. Biochemistry 1982;21:2798-804. heparan sulfate complexes from endothelial cells by plasminogen
113. Baramova EN, Bajou K, Remacle A, L’Hoir C, Krell HW, Weidle activator-mediated proteolytic activity. J Cell Biol 1990;110:767-75.
UH, Noel A, Foidart JM. Involvement of PA/plasmin system in the 125. Stepanova V, Lebedeva T, Kuo A, Yarovoi S, Tkachuk S, Zaitsev S,
processing of pro-MMP-9 and in the second step of pro-MMP-2 Bdeir K, Dumler I, Marks MS, Parfyonova Y, Tkachuk VA, Higazi
activation. FEBS Lett 1997;405:157-62. AA, Cines DB. Nuclear translocation of urokinase-type plasminogen
114. Makowski GS, Ramsby ML. Binding of latent matrix metalloproteinase activator. Blood 2008;112:100-10.

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 6, 2017 287